Clovis Oncology Inc. [NASDAQ: CLVS] price plunged by -4.40 percent to reach at -$0.19. The company report on November 5, 2020 that Clovis Oncology Announces Third Quarter 2020 Operating Results.
$38.8M in Rubraca® (rucaparib) global sales for Q3 2020; net product revenue up 3% over Q3 2019.
Global net product revenue guidance provided for Q4 2020 in a range of $38M to $40M.
A sum of 3861136 shares traded at recent session while its average daily volume was at 4.88M shares. Clovis Oncology Inc. shares reached a high of $4.33 and dropped to a low of $4.12 until finishing in the latest session at $4.13.
The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Clovis Oncology Inc. [CLVS]:
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.36, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 2.38.
CLVS Stock Performance Analysis:
Clovis Oncology Inc. [CLVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.61. With this latest performance, CLVS shares dropped by -31.28% in over the last four-week period, additionally sinking by -57.38% over the last 6 months – not to mention a drop of -36.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 30.92, with the RSI for the last a single of trading hit 31.86, and the three-weeks RSI is set at 36.95 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 5.68, while it was recorded at 4.20 for the last single week of trading, and 6.69 for the last 200 days.
Insight into Clovis Oncology Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Clovis Oncology Inc. [CLVS] shares currently have an operating margin of -256.85 and a Gross Margin at +75.75. Clovis Oncology Inc.’s Net Margin is presently recorded at -280.01.
Return on Total Capital for CLVS is now -58.15, given the latest momentum, and Return on Invested Capital for the company is -63.72. Additionally, CLVS Total Debt to Total Capital is recorded at 132.25, with Total Debt to Total Assets ending up at 106.72.
Reflecting on the efficiency of the workforce at the company, Clovis Oncology Inc. [CLVS] managed to generate an average of -$827,322 per employee. Receivables Turnover for the company is 5.74 with a Total Asset Turnover recorded at a value of 0.19.Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.30.
CLVS Stock EPS
With the latest financial reports released by the company, Clovis Oncology Inc. posted -1.81/share EPS, while the average EPS was predicted by analysts to be reported at -1.71/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -5.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clovis Oncology Inc. go to 66.10%.
Clovis Oncology Inc. [CLVS] Insider Position Details
There are presently around $201 million, or 54.80% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: STATE STREET CORP with ownership of 9,646,730, which is approximately 4.416% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 6,244,924 shares of the stock with an approximate value of $25.79 million in CLVS stocks shares; and BLACKROCK INC., currently with $24.6 million in CLVS stock with ownership of nearly 5.904% of the company’s market capitalization.
Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 93 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 12,063,320 shares. Additionally, 71 investors decreased positions by around 5,547,303 shares, while 30 investors held positions by with 31,003,542 shares. The mentioned changes placed institutional holdings at 48,614,165 shares, according to the latest SEC report filing. CLVS stock had 33 new institutional investments in for a total of 5,922,682 shares, while 28 institutional investors sold positions of 1,725,352 shares during the same period.